Scholarlink

Background/Objectives <p>Immune checkpoint inhibitors are frequently used to treat advanced non-small cell lung cancer (NSCLC). Drug clearance also varies depending on patient-related factors. Therefore, the lung immune prognostic index (LIPI), based on inflammatory markers, may help predict prognosis. Early changes in LIPI may predict treatment response and survival.</p> Methods <p>This multicenter study included 707 patients with NSCLC. LIPI was calculated at baseline and one month after treatment initiation. Patients were categorized into two groups: those with stable or improved LIPI scores and those with worsened LIPI scores. Survival outcomes and prognostic significance were analyzed.</p> Results <p>Median progression free survival was 9 months in patients with stable or improved LIPI and 6 months in those with worsened LIPI (p = 0.005). Median overall survival was 15 months in the stable/improved LIPI group and 9 months in the worsened LIPI group (p = 0.001).</p> Conclusion <p>Changes in LIPI can be assessed using routine laboratory tests as early as the second treatment cycle, allowing early prediction of treatment response. Baseline LIPI values and changes in LIPI can predict prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月21日

查看全文
  • Muhammet Cengiz,
  • Oktay Bozkurt,
  • Ayşe Nuransoy Cengiz,
  • Mevlude Inanc,
  • Metin Ozkan,
  • Emel Mutlu Ozkan,
  • Deniz Can Guven,
  • Mustafa Erman,
  • Latif Karahan,
  • Elif Sahin,
  • Anıl Karakayali,
  • Pervin Can Sanci,
  • Umut Kefeli,
  • Devrim Cabuk,
  • Erdem Kolemen,
  • Mehmet Mutlu Kidi,
  • Sedat Biter,
  • Tolga Koseci,
  • Muslih Urun,
  • Berrak Mermit Ercek,
  • Duygu Bayir,
  • Gözde Agdas,
  • Teoman Sakalar,
  • Nargiz Majidova,
  • Sedat Yildiz,
  • Hacer Demir,
  • Cengiz Akosman,
  • Mustafa Ersoy,
  • Saadettin Kilickap,
  • Erkam Kocaaslan,
  • Ezgi Turkoğlu,
  • Sedat Yildirim,
  • Hayati Arvas,
  • Havva Yesil Cinkir,
  • Aslihan Ezgi Apaydin Rollas

摘要

Background/Objectives

Immune checkpoint inhibitors are frequently used to treat advanced non-small cell lung cancer (NSCLC). Drug clearance also varies depending on patient-related factors. Therefore, the lung immune prognostic index (LIPI), based on inflammatory markers, may help predict prognosis. Early changes in LIPI may predict treatment response and survival.

Methods

This multicenter study included 707 patients with NSCLC. LIPI was calculated at baseline and one month after treatment initiation. Patients were categorized into two groups: those with stable or improved LIPI scores and those with worsened LIPI scores. Survival outcomes and prognostic significance were analyzed.

Results

Median progression free survival was 9 months in patients with stable or improved LIPI and 6 months in those with worsened LIPI (p = 0.005). Median overall survival was 15 months in the stable/improved LIPI group and 9 months in the worsened LIPI group (p = 0.001).

Conclusion

Changes in LIPI can be assessed using routine laboratory tests as early as the second treatment cycle, allowing early prediction of treatment response. Baseline LIPI values and changes in LIPI can predict prognosis.